Addition to Management Team

Intl. Biotechnology Trust PLC
01 June 2005


For immediate release                                             1st June 2005


 INTERNATIONAL BIOTECHNOLGY TRUST STRENGTHENED BY HIGH PROFILE ADDITION TO THE
                           INVESTMENT MANAGEMENT TEAM


International Biotechnology Trust plc ('IBT'), the investment trust managed by
SV Life Sciences ('SVLS') that invests in high growth, development stage
biotechnology companies, announces the addition of Andrew Smith to the IBT
investment management team as IBT Investment Manager. Andrew will join SVLS, the
life sciences focused venture capital adviser and manager, and will form part of
the team that manage the IBT fund which is headed by Kate Bingham.


Andy, (44), brings with him a wealth of commercial and investment management
experience. He moves across from Schroders plc, where he was the lead fund
manager of the Bioscience Investment Trust plc (formerly the 3i Bioscience
Investment Trust plc ('3i Bioscience'), a fund that transferred its management
mandate to Schroders in December 2004. He was also a director and fund manager
in the global equities department.


Prior to the transfer of 3i Bioscience to Schroders, Andy worked for 3i Group, a
private equity and venture capital business, for 4 years where he was the lead
fund manager of 3i Bioscience. During this time he managed and directed globally
diverse funds which invested in quoted and unquoted biotechnology companies.
Previous to this, Andy worked for Smith Kline Beecham, latterly as Global Brand
Manager for new products and formerly in new product research, dermatalogicals
and microbiology. He began his career in a research scientist role in the ICI
Plant Protection Division.


Commenting, Kate Bingham, General Partner of SVLS and lead Manager of the trust,
said: 'We are delighted to welcome Andy on board and I have no doubt that his
experience will strengthen the IBT team. His broad knowledge and expertise in
managing biotech funds will further contribute to the overall growth and
development of the fund.'


Andrew Smith has a B.Sc. (Hons) in Applied Biology (Microbiology) from the North
East London Polytechnic, a Ph.D. in Molecular Biology from the University of
Nottingham and an MBA in International Marketing from the University of
Greenwich. He has written 12 papers in the field of biology, was the inventor on
5 patent applications and has extensive experience in project management gained
from Smith Kline Beecham and grant experience having worked as a lecturer at
Guy's Hospital Medical School. He is married with two children.


For further information please contact:

Kate Bingham
General Partner SVLS, Manager of IBT                     Tel: [phone]

Amy Fisher/Henrietta Guthrie/ Charlotte Edgar
Lansons Communications                                   Tel: [phone]


Notes to editors:

About IBT

The Company's investment objective is to achieve long term capital growth by
investing in high growth, development stage biotechnology companies that are
either quoted or unquoted. IBT invests in companies that are undervalued, with
experienced management and strong potential upside through the development and/
or commercialisation of a product, device or enabling technology.

About SV Life Sciences

SV Life SciencesTM ('SVLS'), previously known as Schroder Ventures Life
Sciences, is a life sciences focused venture capital adviser and manager. SVLS
advised funds invest in companies requiring funding within the human life
sciences sector including biotechnology and pharmaceuticals, medical devices and
instruments, healthcare IT and services. SVLS was established in 1993 and
currently has offices in Boston, London and San Francisco.



                      This information is provided by RNS
            The company news service from the London Stock Exchange